What Is Survodutide? What the Research Actually Shows
Discover what is survodutide, its investigational status, and the current research findings in obesity and metabolic disorders.
By PeptidesDB EditorialPublished Nov 7, 2026Updated Nov 9, 20269 min read
Survodutide, also known as BI 456906, is an investigational peptide that targets both glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is primarily studied for its potential in treating obesity and metabolic disorders such as type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). The dual action of survodutide aims to enhance weight loss and improve glycemic control. Current research in humans has shown promising results in weight reduction, although the long-term safety and effectiveness of survodutide remain under investigation. Understanding what is survodutide involves examining both its potential benefits and the challenges it faces in clinical use.
The short answer
Survodutide, also known by its investigational name BI 456906, is a peptide currently under investigation for its potential therapeutic effects on obesity and metabolic disorders. It functions as a dual agonist, targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This dual action is intended to facilitate weight loss and improve glycemic control, making it a candidate for treating conditions such as type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).
The research on survodutide is still in the investigational stage, with several human clinical trials underway. For example, a study involving 752 adults with obesity and type 2 diabetes demonstrated significant weight loss with survodutide doses of 3.6 mg and 6.0 mg over 76 weeks, compared to placebo source. Another trial reported an 18.7% body-weight reduction at 46 weeks, although it noted uncertainties regarding long-term safety and effectiveness source.
Despite these promising results, the long-term safety profile of survodutide remains a concern, particularly due to reported gastrointestinal side effects. The peptide is administered via subcutaneous injection, and its pharmacokinetics, such as half-life and time to peak, are still being established. For those interested in the technical aspects of peptide preparation, our Peptide reconstitution calculator can be a useful tool. As research progresses, more comprehensive data will be necessary to fully understand survodutide's potential benefits and risks.
What is survodutide and what the term actually covers
Survodutide is a dual agonist peptide that simultaneously targets glucagon-like peptide-1 (GLP-1) and glucagon receptors. This dual action is designed to promote weight loss and improve glycemic control, making it a candidate for treating obesity and metabolic disorders such as type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). The mechanism of action involves the activation of both GLP-1 and glucagon receptors, which are key in regulating appetite and glucose metabolism.
The pharmacological profile of survodutide includes subcutaneous injection as its route of administration, although specific pharmacokinetic parameters such as half-life and time to peak concentration remain unspecified. This suggests that while the peptide is well studied, there is still a need for more detailed pharmacokinetic data to fully understand its behavior in the body.
Research on survodutide has primarily focused on its potential to induce significant weight loss and improve metabolic parameters. For instance, a study involving adults with obesity and type 2 diabetes reported notable weight reductions over 76 weeks. However, the long-term safety and effectiveness of survodutide are still under investigation, as highlighted in a review that points to uncertainties regarding its sustained impact.
Given the investigational status of survodutide, those interested in its potential applications should consider the broader context of peptide safety, which can be explored further in our safety guide. Understanding these aspects is crucial for evaluating the compound's viability as a therapeutic option.
What the evidence shows
The current body of research on survodutide, also known as BI 456906, presents a mixed picture of its potential benefits and challenges. Human clinical trials have demonstrated significant weight loss outcomes. For instance, a study involving 752 adults with obesity and type 2 diabetes showed that survodutide at doses of 3.6 mg and 6.0 mg resulted in an 8.2% reduction in body weight over 76 weeks compared to placebo (source). Another phase 2 trial reported an 18.7% body-weight reduction at 46 weeks, highlighting the compound's potential efficacy in weight management (source).
In addition to weight loss, survodutide has shown promise in reducing liver fat content in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). A phase 3 trial reported that 84.2% of survodutide-treated patients experienced a ≥30% reduction in liver fat content, compared to 24.3% in the placebo group (source).
However, the clinical trials have also noted some concerns. Gastrointestinal side effects were common, raising questions about the compound's tolerability (source). Additionally, while animal studies have suggested potential nephroprotective effects in diabetic kidney disease models, the relevance of these findings to human treatment remains uncertain (source).
For those interested in a deeper dive into survodutide's pharmacological profile and ongoing research, the survodutide profile offers a comprehensive overview. As research progresses, further studies will be necessary to fully understand the long-term safety and efficacy of survodutide in diverse patient populations.
How to think about risk
When considering the potential risks associated with survodutide, it is crucial to weigh both the reported side effects and the uncertainties surrounding its long-term safety. The peptide has shown promise in clinical trials for weight loss and glycemic control, but these benefits are accompanied by notable concerns.
One of the primary risks identified in the research is the prevalence of gastrointestinal side effects. A human randomized controlled trial (5166) reported that while survodutide led to significant weight loss, gastrointestinal issues were common among participants. These side effects could include nausea, vomiting, or diarrhea, which may affect patient compliance and overall treatment success.
Furthermore, a review of survodutide's effects (3278) highlighted higher discontinuation rates due to these adverse effects. This raises concerns about its viability as a long-term treatment option. The review underscores the need for further investigation into the peptide's long-term safety profile, as current data do not provide a comprehensive understanding of its potential risks over extended use.
The absence of long-term safety data is a significant gap in the current research. Future studies should focus on extended follow-up periods to better assess the chronic effects of survodutide. Until such data are available, caution is advised when considering survodutide for therapeutic use. For those interested in exploring more about peptide safety, resources like Are peptides safe? and the research library provide valuable insights. Additionally, the survodutide profile offers detailed information on its pharmacological properties and current research status.
What this site does and does not claim
This site aims to provide a balanced view of survodutide, emphasizing evidence-supported findings without overstating its efficacy or safety. Survodutide, known as BI 456906, is an investigational peptide targeting both GLP-1 and glucagon receptors, primarily researched for obesity and metabolic disorders. Our claims are grounded in the available data from human and animal studies, which have demonstrated significant weight loss outcomes. For instance, a human clinical trial reported a weight change of -8.2% in the 3.6-mg group over 76 weeks in adults with obesity and type 2 diabetes 5237.
However, it is crucial to recognize the limitations and uncertainties that accompany these findings. While survodutide has shown potential benefits, such as an 18.7% body-weight reduction in a phase 2 trial 5236, long-term safety and effectiveness remain uncertain. Side effects, particularly gastrointestinal issues, have been frequently reported, raising concerns about the peptide's tolerability in extended use 5166.
This site does not claim that survodutide is a proven or safe treatment for any condition. The evidence is still evolving, and further studies are necessary to establish its long-term safety profile and clinical relevance. We encourage readers to explore our survodutide profile for detailed information and to consult our Are peptides safe? guide for broader insights into peptide safety. Additionally, our Peptide reconstitution calculator is available for those interested in understanding dosing calculations, though this should not be construed as medical advice.
Common questions
What are the primary benefits of survodutide?
Survodutide is primarily studied for its potential to aid in weight loss and improve glycemic control. Human clinical trials, such as one involving 752 participants, have shown significant weight loss in adults with obesity and type 2 diabetes. For instance, a 3.6 mg dose resulted in an 8.2% weight reduction over 76 weeks compared to placebo (source). Additionally, survodutide has been associated with a reduction in liver fat content in adults with metabolic dysfunction-associated steatotic liver disease (source).
Are there any known side effects?
Yes, survodutide has been linked to gastrointestinal side effects, which are common in the studies reviewed. A phase 2 trial noted higher discontinuation rates due to these side effects, raising concerns about its long-term use (source). The need for further research into these side effects is evident, as long-term safety remains uncertain.
How does survodutide work?
Survodutide functions as a dual agonist, targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This mechanism is designed to enhance weight loss and improve metabolic outcomes, particularly in individuals with type 2 diabetes and related disorders. However, the exact pharmacokinetics, such as half-life and time to peak concentration, are not well-documented in the available studies.
What are the limitations of current research?
While survodutide shows promise, there are limitations in the current research. Most studies focus on short-term outcomes, and there is a lack of data on long-term safety and efficacy. Additionally, while animal studies have shown positive outcomes, their relevance to human treatment is not fully established (source). Future research should aim to address these gaps to provide a clearer understanding of survodutide's potential benefits and risks.
For more detailed information on survodutide, you can refer to its profile or explore the Are peptides safe? guide for broader safety considerations.
Where to go from here
For those interested in delving deeper into survodutide, a few pathways can provide further insights. First, examining the survodutide profile will offer a comprehensive overview of its pharmacological characteristics, investigational status, and current research findings. This profile is a valuable resource for understanding the dual agonist nature of survodutide and its potential applications in treating obesity and metabolic disorders.
Additionally, considering the safety aspects of peptide use is crucial. The Are peptides safe? article provides a thorough exploration of the safety concerns associated with peptides, including survodutide. Given the gastrointestinal side effects and long-term safety uncertainties reported in studies such as the one reviewed in 3278, understanding these risks is essential for anyone considering involvement in research or therapeutic use.
For those involved in experimental or clinical research, practical tools like the Peptide reconstitution calculator can assist in preparing accurate dosages for study purposes. This tool is particularly useful given the specific dosing regimens explored in clinical trials, such as the significant weight loss observed at doses of 3.6 mg and 6.0 mg in a study of 752 participants (5237).
Further research will be needed to solidify survodutide's long-term efficacy and safety profile. Future studies should aim to address the current gaps, such as the long-term impact on metabolic health and the management of side effects. Engaging with ongoing research and staying updated with new findings will be crucial for anyone interested in the potential of survodutide in clinical settings.
Compounds covered